DK1436427T3 - Fremgangsmåde og sammensætning til at vurdere antistofbehandlingsrespons - Google Patents

Fremgangsmåde og sammensætning til at vurdere antistofbehandlingsrespons

Info

Publication number
DK1436427T3
DK1436427T3 DK02782887T DK02782887T DK1436427T3 DK 1436427 T3 DK1436427 T3 DK 1436427T3 DK 02782887 T DK02782887 T DK 02782887T DK 02782887 T DK02782887 T DK 02782887T DK 1436427 T3 DK1436427 T3 DK 1436427T3
Authority
DK
Denmark
Prior art keywords
composition
antibody treatment
treatment response
response
assessing antibody
Prior art date
Application number
DK02782887T
Other languages
Danish (da)
English (en)
Inventor
Herve Watier
Guillaume Cartron
Philippe Colombat
Original Assignee
Chru Tours
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8182931&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1436427(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chru Tours, Innate Pharma filed Critical Chru Tours
Application granted granted Critical
Publication of DK1436427T3 publication Critical patent/DK1436427T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK02782887T 2001-10-19 2002-10-11 Fremgangsmåde og sammensætning til at vurdere antistofbehandlingsrespons DK1436427T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01402718 2001-10-19
PCT/EP2002/011397 WO2003035904A2 (en) 2001-10-19 2002-10-11 Methods and compositions to evaluate antibody treatment response

Publications (1)

Publication Number Publication Date
DK1436427T3 true DK1436427T3 (da) 2008-12-08

Family

ID=8182931

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02782887T DK1436427T3 (da) 2001-10-19 2002-10-11 Fremgangsmåde og sammensætning til at vurdere antistofbehandlingsrespons

Country Status (11)

Country Link
US (3) US7858300B2 (es)
EP (1) EP1436427B1 (es)
JP (1) JP4216720B2 (es)
CN (1) CN1329524C (es)
AT (1) ATE403750T1 (es)
AU (1) AU2002346999B2 (es)
CA (1) CA2463746C (es)
DE (2) DE02782887T1 (es)
DK (1) DK1436427T3 (es)
ES (1) ES2311634T3 (es)
WO (1) WO2003035904A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035904A2 (en) 2001-10-19 2003-05-01 Centre Hospitalier Regional Et Universitaire De Tours Methods and compositions to evaluate antibody treatment response
EP2385137A1 (en) * 2002-07-31 2011-11-09 University of Southern California Polymorphisms for predicting disease and treatment outcome
KR20060038461A (ko) * 2003-07-24 2006-05-03 이나뜨 파르마 Ｎｋ 세포 강화 화합물을 사용하여 치료용 항체의 효율을높이는 방법 및 조성물
GB0324778D0 (en) * 2003-10-23 2003-11-26 Forinnova As Method
MY162179A (en) * 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
RU2006138865A (ru) * 2004-04-07 2008-05-20 Чирон Корпорейшн (Us) Анализы на основе нуклеиновой кислоты для идентификации полиморфизмов fc-рецептора
CA2569196A1 (en) * 2004-06-01 2005-12-15 Centre Hospitalier Regional Et Universitaire De Tours Fcgr3a gebotype and methods for evaluating treatment response to non-depleting antibodies
US20070190657A1 (en) * 2004-06-15 2007-08-16 Universite Francois Rabelais Methods of assessing susceptibility to drug-induced thrombocytopenia
US9109255B2 (en) * 2004-06-18 2015-08-18 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining responsiveness to antibody therapy
AU2005267148A1 (en) * 2004-07-01 2006-02-02 University Of Southern California Genetic markers for predicting disease and treatment outcome
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
KR20080073725A (ko) * 2005-11-01 2008-08-11 노파르티스 아게 항-ｃｄ40 항체의 용도
WO2007053661A2 (en) * 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
CA2631630A1 (en) * 2005-11-30 2007-06-07 University Of Southern California Fc.gamma. polymorphisms for predicting disease and treatment outcome
AU2007244683A1 (en) * 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
CA2675352A1 (en) * 2007-01-18 2008-07-24 University Of Southern California Genetic markers for predicting responsiveness to combination therapy
US20090142763A1 (en) * 2007-08-22 2009-06-04 Wyeth Nested pcr-based method for specific genotyping of the fc gamma receptor iiia gene
US20120070432A1 (en) * 2009-05-28 2012-03-22 Amgen Inc. Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine
EP2383572A1 (en) * 2010-04-28 2011-11-02 Assistance Publique Hôpitaux de Marseille Cellular humoral activation test (CHAT)
KR101938699B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｌｒｉｇ１의 항 ｃ―ｍｅｔ 항체 적용 대상 환자 선별을 위한 용도
KR101938698B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｃｂｌ의 항 ｃ－ｍｅｔ 항체 적용 대상 환자 선별을 위한 바이오마커로서의 용도
FR3037340A1 (fr) 2015-06-09 2016-12-16 Univ Montpellier Methode de pronostic d'hemopathies lymphoides
EP3356561B1 (en) * 2015-10-02 2021-10-27 Momenta Pharmaceuticals, Inc. Therapeutic and diagnostic methods for autoimmune diseases and/or inflammation
US10226088B1 (en) * 2017-03-30 2019-03-12 Robert Russell Pet waste disposable glove
CN108330180A (zh) * 2017-10-25 2018-07-27 广州和康医疗技术有限公司 一种对fcgr3a位点进行基因型检测的方法及试剂盒
CN108676875B (zh) * 2018-04-10 2022-01-18 哈尔滨医科大学 Cd20、fcgriia及fcgriiia基因在弥漫大b细胞淋巴瘤预后中的用途
CA3125503A1 (en) * 2019-01-18 2020-07-23 Acepodia Biotechnologies Ltd. A novel cd16+ natural killer cell and a method of culturing cd16+ natural killer cell
US20230036481A1 (en) * 2020-01-16 2023-02-02 Acepodia Biotechnologies Ltd. A novel cd16+ natural killer cell and a method of culturing cd16+ natural killer cell
CN114277149B (zh) * 2021-12-30 2023-09-22 苏州方科生物科技有限公司 一种检测cd16a基因多态性的试剂盒及其应用和使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446314A (en) * 1980-09-30 1984-05-01 Cutter Laboratories, Inc. Fractionation of heparin
ES2262163T3 (es) * 1988-05-27 2006-11-16 Applied Research Systems Ars Holding N.V. Receptor iii de fc gamma humano.
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0633268B1 (en) * 1993-05-14 2004-07-28 Cancer Institute MDC proteins and DNAs encoding the same
US5830652A (en) * 1994-08-30 1998-11-03 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method for determining predisposition to severe forms of autoimmune disease by determining Fcy receptor allelic patterns
US5866337A (en) * 1995-03-24 1999-02-02 The Trustees Of Columbia University In The City Of New York Method to detect mutations in a nucleic acid using a hybridization-ligation procedure
US6444789B1 (en) * 1995-05-03 2002-09-03 Applied Research Systems Ars Holding N.V. CD16-II variants
WO1997046715A1 (en) * 1996-06-03 1997-12-11 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Fc receptor polymorphism
ATE211740T1 (de) * 1996-06-27 2002-01-15 Pfizer Substituierte indazolderivate
US6676927B1 (en) * 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies
GB9919194D0 (en) 1999-08-14 1999-10-20 Univ Leeds Genetic marker for rheumatoid arthritis
EP1130122A3 (en) * 2000-02-17 2001-10-17 AstraZeneca AB Methods for the diagnosis of polymorphisms in the human EP1-R gene
WO2003035904A2 (en) * 2001-10-19 2003-05-01 Centre Hospitalier Regional Et Universitaire De Tours Methods and compositions to evaluate antibody treatment response
US20070231813A1 (en) * 2004-06-01 2007-10-04 Centre Hospitalier Regional Et Universitaire De Tours Fcgr3a Gebotype and Methods for Evaluating Treatment Response to Non-Depleting Antibodies
US20070190657A1 (en) * 2004-06-15 2007-08-16 Universite Francois Rabelais Methods of assessing susceptibility to drug-induced thrombocytopenia

Also Published As

Publication number Publication date
CA2463746C (en) 2014-09-02
CN1571850A (zh) 2005-01-26
DE60228108D1 (de) 2008-09-18
ATE403750T1 (de) 2008-08-15
US20150017633A1 (en) 2015-01-15
EP1436427A2 (en) 2004-07-14
EP1436427B1 (en) 2008-08-06
WO2003035904A2 (en) 2003-05-01
US20110123996A1 (en) 2011-05-26
AU2002346999B2 (en) 2007-11-08
CN1329524C (zh) 2007-08-01
CA2463746A1 (en) 2003-05-01
JP4216720B2 (ja) 2009-01-28
US7858300B2 (en) 2010-12-28
ES2311634T3 (es) 2009-02-16
US20050064417A1 (en) 2005-03-24
JP2005506093A (ja) 2005-03-03
DE02782887T1 (de) 2005-01-13
WO2003035904A3 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
DK1436427T3 (da) Fremgangsmåde og sammensætning til at vurdere antistofbehandlingsrespons
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
HUP0301877A2 (hu) Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek
EA200800879A1 (ru) Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов
MX2019005415A (es) Anticuerpos de il-6 y uso de los mismos.
BRPI0414030A (pt) método para detectar desordens neoplásicas em uma amostra corporal solubilizada
DK1682074T3 (da) Præparater og fremgangsmåder til sund graviditet
NO20044462L (no) Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer
ATE442592T1 (de) Detektion und/oder beobachtung von synuclein- assoziierten krankheiten
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
CY1108630T1 (el) Εξεταση βιοισοδυναμιας δια συνθεσεις οι οποιες περιεχουν σιδηρο
DE60326214D1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
IL179441A (en) Method of measuring the activity of egln enzyme and of identifying an agent that modulates activity of said enzyme
IL174195A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
NO20065859L (no) Bruk av IL-17 behandlingen av fertilitetsrelaterte lidelser
DK1509618T3 (da) Autoimmune sygdomme og NADPH-oxidasedefekter
WO2009043848A3 (en) Use of the serological assay of the cytokine b-lymphocyte stimulator (blys) for the diagnosis, prognosis and the screening of therapeutic efficacy in immune-related diseases including organ-specific autoimmune diseases and transfusion reactions
HUP0203408A2 (hu) Eljárás hiperlipémia elleni preventív vagy terápiás hatóanyag tesztelésére
DK1441708T3 (da) Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme
SE0202897D0 (sv) Method and kit for quantitative and qualitative determination of human papillomavirus
DE602004029156D1 (de) Prognose des verlaufs einer krebserkrankung
ATE393243T1 (de) Diagnostisches verfahren der mastozytose
EP1495056A4 (en) ANTIBODY DISULFIDISOMERS, THEIR USE AND METHOD FOR THEIR ANALYSIS
WO2004034994A3 (en) Methods and compositions for determining risk of treatment toxicity
Al-Abdulla et al. Improving clinical outcomes for type 2 diabetes patients using teleconsultations during the COVID-19 pandemic